This study focuses on children and adolescents living with Osteogenesis Imperfecta, a rare genetic condition that causes bones to be fragile and more likely to break. The purpose of the study is to evaluate the safety of a medication called romosozumab in individuals who have previously used this treatment.
Participants in this research have already completed a prior study involving the administration of romosozumab via subcutaneous injection, which is a method of delivering medication through a needle into the fatty layer of the skin just under the surface. The study involves monitoring these individuals over time to observe any adverse events, which are unexpected or undesirable medical occurrences that may happen after using a drug.
Austria 
Belgium 
Germany 
Hungary 
Italy 
Slovakia 
Spain 
